Amorfix developing ALS diagnostic tool

Amorfix Life Sciences (TSX:AMF) is developing a blood test to be used as a diagnostic tool for amyotrophic lateral sclerosis (ALS) based on initial ground breaking scientific study results of its CSO, Dr. Neil Cashman, and colleagues at UBC, who have shown that misfolded SOD1 is present in the blood of ALS patients. Amorfix said [...]

Amorfix produces high-affinity antibodies to DSEs

Amorfix Life Sciences (TSX:AMF), together with its partner, has produced high-affinity antibodies to prion protein disease-specific epitopes (DSEs), which bind preferentially to several cancer primary cells and tumour cell lines, but not normal cells. “This represents a significant milestone for our cancer therapeutic antibody program,” CEO Dr. Robert Gundel said in a statement. “The generation [...]

Amorfix in ALS vaccine license with Pan-Provinical

Amorfix Life Sciences (TSX:AMF) has granted Pan-Provincial Vaccine Enterprise of Saskatoon exclusive worldwide rights to Amorfix’s lead amyotrophic lateral sclerosis vaccines, which have shown efficacy in animal models of ALS. Under the accord, Pan will develop vaccine formulations, finish preclinical studies for regulatory approvals and conduct clinical testing of the vaccines at their cost.  Upon [...]

Theratechnologies CEO retires; Amorfix’s steps down

Yves Rosconi, CEO and President of Theratechnologies (TSX:TH), has informed the board of his decision to retire on Dec. 31, 2010, saying he deferred his decision until the company’s lead tesamorelin product was in the final stages of the FDA approval process. A strategic committee of the board will immediately begin the formal search for [...]